Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
about
Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapyCellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerTargeting DNA damage response in cancer therapyCell cycle checkpoint in cancer: a therapeutically targetable double-edged swordChemical strategies for development of ATR inhibitorsTrovafloxacin enhances lipopolysaccharide-stimulated production of tumor necrosis factor-α by macrophages: role of the DNA damage response.Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970Replication stress by Py-Im polyamides induces a non-canonical ATR-dependent checkpoint response.The role of master regulators in the metabolic/transcriptional coupling in breast carcinomasEfficient herpes simplex virus 1 replication requires cellular ATR pathway proteinsAtaxia telangiectasia mutated and Rad3 related (ATR) protein kinase inhibition is synthetically lethal in XRCC1 deficient ovarian cancer cells.ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.Herpes simplex virus type 1 single strand DNA binding protein and helicase/primase complex disable cellular ATR signaling.DNA repair gene polymorphisms and clinical outcome of patients with primary small cell carcinoma of the esophagus.Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-relatedAnalysis of functional germline variants in APOBEC3 and driver genes on breast cancer risk in Moroccan study population.Characterization of Cardiac Glycoside Natural Products as Potent Inhibitors of DNA Double-Strand Break Repair by a Whole-Cell Double Immunofluorescence Assay.The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapyRepairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanismsTargeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition.AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.RAD53 is limiting in double-strand break repair and in protection against toxicity associated with ribonucleotide reductase inhibitionMolecular targets and mechanisms of radiosensitization using DNA damage response pathways.Chemotherapy induced DNA damage response: convergence of drugs and pathwaysInhibiting the DNA damage response as a therapeutic manoeuvre in cancer.A patient-derived-xenograft platform to study BRCA-deficient ovarian cancers.Expression of base excision repair key factors and miR17 in familial and sporadic breast cancerRadiosensitization by the ATR Inhibitor AZD6738 through Generation of Acentric Micronuclei.Host DNA damage response factors localize to merkel cell polyomavirus DNA replication sites to support efficient viral DNA replication.Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication.Selective tumor killing based on specific DNA-damage response deficiencies.Inhibiting homologous recombination for cancer therapy.Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer.HSV-I and the cellular DNA damage response.Molecular Pathways: Targeting ATR in Cancer TherapyDNA replication stress and cancer: cause or cure?
P2860
Q26745686-CDF12FC4-0D2B-4EA1-8196-BA486D5A8504Q26771165-00CEDB73-70F2-4761-8D54-61EB0133E5D8Q26776513-7ECA5796-103C-444B-8966-310A264E0F03Q27023204-3D2973CE-3526-4A8B-8AAA-3A1C8C10596EQ28078268-A7CB07F6-58BD-4779-88D1-D7CE55721D3CQ28239738-DAB511B8-5EB8-43B2-8496-9F4951A18556Q33750834-B4A5F45E-FE5C-42C3-928C-BF4740992801Q33917547-35758F9F-50E3-4DFD-80CD-04CF2A50F2E5Q34221860-3ABB9CBE-0EE5-4601-95DC-03A5ABDBEB0CQ34313126-7F619101-2414-47E2-9D8E-64AE6E20F6D2Q34404780-200F67AA-46E9-4833-9C68-DCEA05BB9A9AQ34457674-CFA1D49B-CB11-47FB-919F-B4DE05E4913EQ34603025-7A6A88B7-E8A0-49F7-88C4-9C3346F17537Q34614944-84D39C42-CB2A-4D70-B455-51EB1FBD6535Q35008795-63FB1D80-78EA-48FF-B0CC-6EDD4276F929Q35221075-1F8EB3CF-3C35-4D78-B056-C0088674FCF2Q35246419-7EA00D4F-5445-4203-8D5B-77440FD24607Q35651970-735BEAAD-DBF6-4ADD-8C5C-C04B10838539Q35937737-8AB443CD-35D1-4619-8D69-45298EC794F6Q35940003-687891EA-A343-43E5-BDF5-EFC2ADCC1C38Q36289912-CD1EA338-67E7-411C-A0E1-6BED0B39BD51Q36413288-3C2ECF28-CFDB-4DEE-B897-D1DD39879FCDQ36525188-D41B09B6-BD5A-46FE-8E46-9E89C442AFCBQ36544857-6F6C42D7-5778-4C98-9B56-91200EE595DFQ36757444-D0BF03A5-D32D-4461-AFFA-1BBDF694D5F2Q36780916-BD485500-75BA-40E7-A549-B42A60BD11C7Q36792626-E99F3326-985E-45A3-A485-CAA76D7AC19AQ36901484-2CBCA3D1-4E64-43D7-8217-58D241889E93Q37122690-0EADA5A4-B63A-40A5-AE2A-FEDD9572C3F9Q37558633-D2DA624A-AA74-46E3-A323-6EDDE66B8F75Q37620662-5D1D4D54-2CE0-4A6D-88BF-1EC3305A6952Q37635766-4B2CF483-BB16-4D9E-9A2E-687DA11584FBQ37643764-522FBC65-32FF-4482-8D2C-EE431B63CC26Q37936675-1B12EC1E-B940-4E02-BDC2-2DDD838420D1Q37976982-7421F4D7-5E80-41FF-998E-2B0CD8F2E021Q37984197-384482E8-2F37-4DA7-91DB-DCAFDA11DCCAQ38523589-147017CC-0A64-4921-8F03-E57AC5DD3BE0Q38554935-4F5B8F36-2D18-48DD-9ED8-74EEE7F8D5BEQ38585436-924C093C-55B5-4F42-BE97-8F0E8E3E7557Q38652528-6416F322-D95C-4C4A-B411-05E1E4E8689C
P2860
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Identification and evaluation ...... and ovarian cancer cell lines
@ast
Identification and evaluation ...... and ovarian cancer cell lines
@en
type
label
Identification and evaluation ...... and ovarian cancer cell lines
@ast
Identification and evaluation ...... and ovarian cancer cell lines
@en
prefLabel
Identification and evaluation ...... and ovarian cancer cell lines
@ast
Identification and evaluation ...... and ovarian cancer cell lines
@en
P2093
P2860
P356
P1476
Identification and evaluation ...... and ovarian cancer cell lines
@en
P2093
A Peasland
J Sarkaria
R J Edmondson
P2860
P2888
P304
P356
10.1038/BJC.2011.243
P407
P577
2011-07-05T00:00:00Z